Cephalon Recommends Shareholders Reject Valeant's Consent Solicitation to Remove Cephalon's Board of Directors

Cephalon, Inc. CEPH today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission urging shareholders to reject Valeant Pharmaceuticals International Inc.'s VRX proposals to remove Cephalon's entire Board of Directors and replace them with nominees hand-picked by Valeant. The Cephalon Board of Directors recommends that Cephalon shareholders reject Valeant's proposals and not deliver any gold consent solicitation cards to Valeant.